Key Highlights

  • Sunshine Biopharma (NASDAQ:SBFM) rose 5.28% to USD 2.79 in pre-market trading on Tuesday, October 27, 2026, after pricing a USD 6.0 million public offering of units with Series D Warrants, whose USD 0.55 unit price is not directly comparable with the quote.
  • Telomir Pharmaceuticals (NASDAQ:TELO) gained 5.16% to USD 1.0500, a quote about 9.5% below the USD 1.16 price of a private placement that included no warrants, according to simple arithmetic on two published figures.
  • Masonglory Limited (NASDAQ:MSGY) fell 7.74% to USD 3.22 after a registration statement for a securities offering was filed with the SEC on Friday, October 23, 2026, although the size and terms are not specified.
  • Alpha Modus Holdings, Inc. (NASDAQ:AMOD) fell 7.50% to USD 0.98, about 14.8% below the USD 1.15 price of a registered direct offering announced on Wednesday, October 21, 2026.

Sunshine Biopharma (NASDAQ:SBFM): units with two warrants each

Sunshine Biopharma (NASDAQ:SBFM), a Canadian generic pharmaceutical seller with oncology and antiviral research programmes, traded in a pre-market snapshot. No company-specific announcement dated on or just before Tuesday, October 27, 2026 was identified. The most recent corporate event is the company's release of Thursday, October 8, 2026, which priced the offering of 10,909,083 units at USD 0.55, led by Aegis Capital Corp. as exclusive placement agent. Each unit included two Series D Warrants exercisable at USD 0.66 and expiring five years after issuance. The move appears consistent with thin liquidity following the financing.

Results for the six months ended June 30, 2026, reported in August 2026, show revenue of USD 17.4 million, down 5% year on year, and gross profit of USD 4.6 million, a margin of 26.5%. Cash and equivalents were USD 13.7 million, up 51% with USD 7.8 million of financing proceeds.

The overhang here comes from warrants as much as shares. Named risks are dilution from the offering, the Series D Warrants and a USD 4 million at-the-market agreement signed in July 2026, together with margin pressure and the early stage of the K1.1 mRNA liver cancer programme.

Telomir Pharmaceuticals (NASDAQ:TELO): a placement without warrants

Telomir Pharmaceuticals (NASDAQ:TELO), a clinical-stage company developing Telomir-Zn, an investigational compound targeting metal-dependent disease pathways, traded in a pre-market snapshot below its placement price. No company-specific announcement dated on or just before Tuesday, October 27, 2026 was identified. The latest corporate event is the company's release of Tuesday, October 6, 2026, which announced a private placement of about USD 5.6 million from 4,843,300 shares, a 5% discount to the 10-day volume-weighted average price, plus a further USD 1.0 million from an individual investor. Proceeds are earmarked mainly for the Phase 1/2 programme in advanced or metastatic triple-negative breast cancer. The advance appears consistent with thin pre-market liquidity after the financing.

The quarterly report for the period ended June 30, 2026 shows a net loss of USD 1,721,528 and cash of USD 5,170,286, against USD 7,286,670 at December 31, 2025. Management states substantial doubt about continuing as a going concern, so the placement addresses an immediate funding need.

Telomir shows the cleaner form of the driver, since new shares dilute holders while funding reduces near-term solvency risk. The bull reading rests on the FDA clearance of the investigational new drug application on Thursday, April 30, 2026 for a first-in-human study of about 76 patients. The bear reading rests on the going concern statement and on first-in-human clinical risk.

Masonglory Limited (NASDAQ:MSGY): a registration statement with no stated size

Masonglory Limited (NASDAQ:MSGY), a Hong Kong subcontractor that provides wet trades, meaning plastering, tile laying, brick laying, floor screeding and marble works, traded in the pre-market snapshot of Tuesday, October 27, 2026. The implied prior close of about USD 3.49 matches the closing price of Monday, October 26, 2026. The decline appears consistent with the prospect of new share supply, which is a common source of selling pressure in small capitalisation stocks, although the size and terms of any offering are not specified.

The annual report published on Thursday, July 30, 2026 shows fiscal year 2026 revenue of USD 23.6 million, up 1%, and gross profit of USD 1.0 million, a margin of 4.4% against 9.3%. The net loss of USD 8.0 million was attributed mostly to a one-time, non-cash share-based compensation expense of USD 7.8 million. Backlog, meaning contracted work not yet performed, rose 111% to USD 31.4 million, while cash at banks was USD 0.3 million at March 2026.

That small cash balance makes external funding likely, which is why a registration statement carries weight. The company also announced a USD 1.0 million private placement on Monday, September 28, 2026 to fund the acquisition of equity interests in Beta Beteiligungs und Besitz GmbH. Named risks are dilution, concentration in a single Hong Kong construction market and a Nasdaq minimum bid price deficiency notice of Tuesday, March 17, 2026.

Alpha Modus Holdings, Inc. (NASDAQ:AMOD): shares priced above the quote

Alpha Modus Holdings, Inc. (NASDAQ:AMOD), a technology and intellectual property company that develops, licenses and enforces data-driven systems for consumer engagement in physical retail, traded in the pre-market snapshot of Tuesday, October 27, 2026. The company's release of Wednesday, October 21, 2026 announced definitive agreements for a registered direct offering of 6,304,348 common shares, expected to close on or about Thursday, October 22, 2026, with H.C. Wainwright & Co. as exclusive placement agent. The quote sitting below the offering price appears consistent with selling by new holders and the added share supply.

The company's filings show a net loss of USD 8.0 million for 2025, against net income of USD 4.1 million for 2024, and royalty revenue of USD 7,138 in 2025. Cash was USD 35,508 at March 31, 2026, with a working capital deficit of USD 5.5 million, and the filing states that substantial doubt exists about the ability to continue as a going concern. The offering of about USD 7.25 million gross is intended to repay certain indebtedness and for general corporate purposes.

The bull reading rests on the use of proceeds, because repaying indebtedness would reduce the working capital deficit. The bear reading rests on the absence of operating revenue and on the quote now sitting below USD 1.00, which raises minimum bid price compliance questions alongside dilution.

Where Things Stand

The answer is that offering and warrant overhang explains the four moves only partly, because each financing meets the market differently. Sunshine Biopharma (NASDAQ:SBFM) carries warrants, Telomir Pharmaceuticals (NASDAQ:TELO) priced above its quote without warrants, Masonglory Limited (NASDAQ:MSGY) faces supply of unstated size and Alpha Modus Holdings, Inc. (NASDAQ:AMOD) trades below its offering price. Pre-market liquidity is thin in all four.

The next catalysts are the Federal Reserve decision on Wednesday, October 28, 2026, the terms of the Masonglory offering, the closing confirmation at Alpha Modus and the third quarter reports at Sunshine Biopharma and Telomir. Pre-market prices are snapshots and can change before the open at 9:30 a.m. ET, and this is not investment advice.